SCHEMBL30947342

SCHEMBL30947342

CN(Cc1ccc(Oc2ccc(CNc3c(N)c(Cl)nc4ccccc34)cc2)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
EGFR P00533 1/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
NCF1 P14598 1/20 0.37
GBA1 P04062 1/20 0.36
POLB P06746 1/20 0.36
RAD52 P43351 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PDE5A O76074 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27213620 0.90 APP (0.42) APPKMT2AMEN1EGFRNCF1
SCHEMBL29977361 0.87 EGFR (0.51) KMT2AMEN1EGFRNPC1GAA
SCHEMBL29381485 0.82 KMT2A (0.50) APPKMT2AMEN1NPC1GAA
SCHEMBL21013099 0.82 KMT2A (0.50) APPKMT2AMEN1NPC1GAA
SCHEMBL28802725 0.77 POLB (0.47) APPKMT2AEGFRNCF1POLB
SCHEMBL212644 0.76 KMT2A (0.47) APPKMT2AMEN1NPC1GAA
SCHEMBL213444 0.76 APP (0.62) APPKMT2AEGFRNCF1POLB
SCHEMBL27744435 0.75 KMT2A (0.42) APPKMT2AMEN1EGFRNCF1
SCHEMBL211489 0.75 POLB (0.51) APPKMT2AGAAPOLBRAD52
SCHEMBL30947343 0.74 HTR2C (0.40) KMT2AMEN1GBA1HTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 APP 3439/4885KMT2A 2443/4885MEN1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.